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Introduction: Sympathetic overactivity is thought to be a
major contributor to the pathogenesis and progression of
human hypertension [1, 2]. In particular, renal sympathetic
activation results in renal vasoconstriction, increased renin
secretion, and enhanced sodium and water reabsorption, all
of which contribute to the development of hypertension [3].
Despite this mechanistic understanding, attempts at modu-
lating sympathetic tone with antiadrenergic drug therapy
have been limited by their poor clinical performance and
undesirable side-effect profile [1, 4]. Additionally, historic
surgical approaches for the treatment of hypertension with
renal sympathectomy have long been abandoned due to a
high perioperative morbidity and mortality [5, 6]. In recent
years, the advent of a catheter-based technique using
radiofrequency to destroy the renal nerves has revitalized
these long abandoned thoughts of treating hypertension with
renal denervation. Following encouraging results of an
uncontrolled feasibility trial and a case report [7, 8], a recent
randomized controlled trial (Symplicity HTN-2 [Renal
Denervation in Patients With Uncontrolled Hypertension])
has further demonstrated the potential for catheter-based renal
denervation in the treatment of drug-resistant hypertension.
Aims: The Symplicity HTN-2 trial was designed to
determine the safety and effectiveness of catheter-based
renal artery denervation with the Symplicity Catheter
System (Ardian, Palo Alto, CA) in reducing blood pressure
in patients with drug-resistant hypertension.
Methods: In this multicenter trial (involving 24 centers in
Europe, Australia, and New Zealand), 106 patients ages 18
to 85 years with a systolic blood pressure of 160 mm Hg or
more (≥150 mm Hg in patients with type 2 diabetes),
despite treatment with three or more antihypertensive
medications were randomized to undergo renal denervation
while continuing prior drug therapy or to continue prior
drug therapy alone. Patients who met initial screening
criteria were subsequently excluded from the trial if their
blood pressure fell below eligibility criteria at a second
clinic visit after a 2-week screening phase. During this
phase, patients were required to document medication
compliance and twice-daily home blood pressure monitor-
ing. Patients were also excluded if they were found to have
unfavorable renal artery anatomy on imaging; other
exclusion criteria included an estimated glomerular filtra-
tion rate of less than 45 mL/min/1.73 m
2 and type 1
diabetes. The trial’s primary end point was the change from
baseline in seated office-based measurement of systolic
blood pressure at 6 months.
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DOI 10.1007/s11886-010-0166-xDuring the intervention, the catheter was advanced into
the renal arteries and four to six discrete low-power
radiofrequency treatments were applied along the length
of both renal arteries. Background use of antihypertensive
drugs was held constant for the duration of the trial in both
groups.
Results: At baseline, the groups were well matched on most
characteristics: office blood pressure was 178/96 mm Hg in
the intervention group (n=52) and 178/97 mm Hg in the
control group (n=54). Office-based blood pressure fell by
32/12 mm Hg (SD 23/11; P<0.001) in the patients who
underwent renal denervation versus no change in the control
group (1/0 mm Hg, SD 21/10; P=NS). Home blood pressure
fell by 20/12 mm Hg (SD 17/11) in the renal denervation
group (n=32) versus no change in the control group (n=40).
Twenty-four-hour ambulatory blood pressure fell by 11/
7 mm Hg (SD 15/11; P<0.006) in the renal denervation
group (n=20) versus no change in the control group (n=25).
There were no serious procedural complications in the
denervation group and no between-group differences in renal
function or in the incidence of adverse events.
Discussion: The authors concluded that renal artery
denervation is safe and effective in reducing office blood
pressure, home blood pressure, and 24-h blood pressure at
6 months in patients with drug-resistant hypertension.
Comments
The Symplicity HTN-2 trial is the first randomized
controlled trial evaluating catheter-based renal denervation
for the treatment of hypertension. The results demonstrate a
dramatic reduction in blood pressure in patients with severe
drug-resistant hypertension. Thus, Symplicity HTN-2 is a
landmark study in the rapidly developing field of invasive
device-based therapy for hypertension [1].
The trial has several notable strengths. The research
design was both rigorous and innovative, overcoming
challenges of research methodology for evaluating device-
based therapy in hypertension [1]. Simply enrolling
hypertensive subjects into clinical trials can lead to large
nonspecific decreases in blood pressure due to regression to
the mean and the Hawthorne effect, the later related to
increased medication adherence. The Symplicity HTN-2
investigators effectively eliminated these confounding
effects by requiring that blood pressure be elevated on
two sequential screening visits before enrollment, and by
having patients focus on their blood pressure and medica-
tion adherence by giving them home blood pressure
monitors and medication logs between screening visits.
Nineteen percent of initially eligible subjects failed repeat
screening. That the control group had no change in blood
pressure at the end of the 6-month trial speaks to the
effectiveness of this clever and powerful design. Blood
pressure variability was further reduced by 1) automatic
blood pressure monitoring in the office, thus reducing
interobserver variability; 2) restricting medication changes
during the trial; and 3) using experienced research teams in
hypertension centers of excellence to conduct the study.
The observed reduction of blood pressure with renal
denervation was substantial. A reduction in office blood
pressure of 32/12 mm Hg, if sustained, would be expected
to dramatically reduce cardiovascular morbidity and mor-
tality in this high-risk group. The treatment effect was
robust as demonstrated by significant decreases in home
and ambulatory blood pressure, which more accurately
reflect aggregate blood pressure burden on the cardiovas-
cular system and are thus more predictive of hypertensive
complications [2].
This study also has several limitations. Nearly 20% of
patients screened for enrollment were ineligible due to
unfavorable renal anatomy, placing limits on potential
clinical application. The sample size was too small and
duration of follow-up too short to permit evaluation of hard
clinical outcomes and the potential for reinnervation. Lack
of a sham denervation control and lack of blinding to
condition assignment are inherent limitations of this type of
trial. This limitation notwithstanding, an invasive sham
procedure is often logistically difficult to perform and does
not ensure adequate blinding of patients and investigators.
Only half of the cohort was evaluated by ambulatory blood
pressure monitoring, a key research tool especially for
evaluating a treatment based on sympathetic mechanisms
(which mediate blood pressure surges typified by the
“white coat” effect) [2]. The observed reduction in
ambulatory blood pressure was one-third the magnitude of
the reduction in office blood pressure, suggesting a more
conservative estimate of the treatment effect.
The mechanism by which renal artery denervation
improves blood pressure control is fascinating and as yet
incompletely understood. Although the article’s title indicates
that the mechanism of the treatment effect is denervation of
the renal sympathetic efferent nerve fibers, denervation of
renal afferent (sensory) nerve fibers may play an additional
role. Activation of renal afferent nerves is thought to trigger
central sympathetic activation and contribute to hypertension
in the setting of chronic renal failure [9]. The present study
raises the intriguing possibility that renal afferent denervation
could be the main mechanism of the therapeutic effect in
Symplicity HTN-2. A better mechanistic understanding of
the observed reduction in blood pressure will require
measuring specific effects of radiofrequency ablation on
renal sympathetic nerve function—renal blood flow, plasma
renin activity, and renal sodium excretion.
94 Curr Cardiol Rep (2011) 13:93–95Overall, the results of the Symplicity HTN-2 trial are very
exciting and undoubtedly will fuel much more research on
invasive device-based antihypertensive therapy not only for
drug-resistant primary hypertension but also for mild primary
hypertensionand secondary hypertensiondue to chronic renal
failure. The public health implications would be staggering if
a one-time invasive procedure could replace a lifetime of
antihypertensive medication for a fraction of the 1 billion
people with hypertension worldwide [10]. In the context of
this proof-of-concept trial, renal denervation proved to be an
effective adjunct—not a replacement—for multidrug treat-
ment of difficult hypertension. Is radiofrequency ablation a
cure for hypertension? Not yet.
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